Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...
A bench of justices, Anil Kshetarpal and Harish Vaidyanathan Shankar said the judge’s approach undermined judicial conscience ...
Two children with a rare genetic condition will live very different lives because one was tested at birth and the other was not, their parents say. Marley, five, and Meadow, four months, both have ...
The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age ...
SCHAUMBURG, Ill., Nov. 26, 2025 /PRNewswire/ -- Cure SMA, the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of ...
Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...
Zacks.com on MSN
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA ...
Comic Samay Raina faced the Supreme Court's ire for jokes about Spinal Muscular Atrophy (SMA) sufferers. The court suggested ...
Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...
Novartis ( NVS) on Monday said that the U.S. FDA has approved Itvisma for the treatment of children two years and older, ...
Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III ...
SMA is a rare, genetic neuromuscular condition that affects people across age groups. With treatment landscapes evolving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback